Alpha Tau Medical (DRTS) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Tau Medical (DRTS) has outperformed Replimune Group (REPL) over the past year, gaining 245.0% versus a gain of 183.9%. Over five years, DRTS leads with a +44.1% price change compared with -56.2% for REPL. Alpha Tau Medical is the larger company by market cap ($1.29 billion vs $1.23 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRTS | REPL |
|---|---|---|
| Share price | $14.00 | $13.04 |
| Market cap | $1.29B | $1.23B |
| 1-day change | -1.75% | -1.21% |
| YTD return | +187.88% | +35.80% |
| 1-year return | +245.04% | +183.87% |
| 5-year return | +44.08% | -56.22% |
| EPS (TTM) | $-1.04 | $-3.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.79 | $16.33 |
| 52-week low | $3.43 | $1.50 |
| Distance from 52-week high | -11.34% | -20.15% |
| Analyst consensus | none | buy |
| Avg. price target upside | +27.14% | +49.54% |
| Average volume | 566.95K | 4.17M |
| Shares outstanding | 92.48M | 94.22M |
| Employees | 121 | 465 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DRTS has outperformed REPL by 61.2 percentage points over the past year.
About Alpha Tau Medical
DRTS stock →Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
Health Care · Medical/Dental Instruments · 121 employees
About Replimune Group
REPL stock →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 465 employees
DRTS vs REPL FAQ
Which is bigger, Alpha Tau Medical or Replimune Group?
Alpha Tau Medical (DRTS) is larger, with a market capitalization of $1.29B compared with $1.23B for Replimune Group (REPL).
Which stock has performed better over the past year, DRTS or REPL?
DRTS returned +245.04% over the past 12 months, compared with +183.87% for REPL (price return, excluding dividends). Past performance does not predict future results.
Are Alpha Tau Medical and Replimune Group in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Alpha Tau Medical and Biotechnology: Biological Products (No Diagnostic Substances) for Replimune Group.